compar
effici
differ
promot
firefli
luciferas
fluc
gene
clone
gener
use
studi
control
three
addit
fluc
express
plasmid
contain
differ
promot
construct
replac
cmv
promot
ccmv
complet
cmv
promot
scmv
cag
ltr
gener
pscmvfluc
pcagfluc
pltrfluc
respect
cell
transfect
aforement
four
plasmid
rel
light
unit
rlu
analyz
hour
posttransfect
demonstr
highest
rlu
valu
construct
pscmvfluc
carri
complet
cmv
promotor
found
effect
drive
gene
express
note
wide
use
make
pseudotyp
viru
howev
low
titer
pseudovirus
make
unsuit
lot
experi
particularli
vivo
assay
requir
viral
titer
least
tuml
improv
titer
pseudoviru
introduc
rabi
pseudotyp
viru
previous
use
backbon
plasmid
valid
hiv
neutral
assay
high
titer
pseudotyp
virus
howev
could
directli
use
make
rabi
gpseudotyp
viru
lack
report
gene
backbon
plasmid
therefor
clone
fluc
gene
end
silenc
env
gene
gener
next
set
determin
optim
pair
g
protein
express
plasmid
differ
backbon
plasmid
fluc
gene
replac
cv
glycoprotein
gene
aforement
fluc
express
plasmid
differ
promot
gener
pscmvcv
c
pcagcv
pltrcv
l
respect
gener
variou
form
pseudovirus
n
f
fc
cotransfect
separ
four
g
protein
express
plasmid
cell
twelv
form
pseudotyp
virus
gener
subsequ
use
infect
cell
fortyeight
hour
postinfect
rlu
determin
found
pair
pcagcv
could
produc
highest
rlu
valu
data
shown
optim
condit
gener
test
ratio
pcagcv
end
ratio
pcagcv
rang
investig
found
ratio
ideal
yield
highest
titer
pseudotyp
viru
reach
high
found
pcagcv
best
combin
next
investig
cell
type
gener
rabi
pseudoviru
achiev
seven
type
cell
test
includ
mdck
bsr
vero
titer
rabi
pseudoviru
gener
differ
cell
line
compar
use
oneway
analysi
varianc
anova
show
signific
differ
n
p
fig
cell
best
cell
substrat
pseudoviru
neutral
assay
next
determin
optim
number
cell
rabi
viru
product
toward
end
titrat
rabi
pseudotyp
viru
wide
rang
cell
number
found
yield
highest
titer
equal
concentr
viru
prepar
use
fig
titer
rabi
pseudoviru
detect
differ
cell
number
compar
use
oneway
anova
show
signific
differ
n
p
furthermor
pair
comparison
student
test
perform
signific
differ
p
observ
differ
also
found
insignific
note
linear
correl
coeffici
r
obtain
cell
inoculum
found
greater
reveal
excel
linear
curv
fit
moreov
neutral
assay
perform
differ
cell
number
valu
maxim
inhibitori
concentr
valu
similar
cell
inocula
rang
fig
howev
input
cell
number
less
variat
valu
would
increas
dramat
given
find
chosen
subsequ
experi
next
test
viral
inocula
dose
rang
start
vitro
neutral
assay
chines
nation
refer
sampl
iuml
intern
control
sampl
design
sampl
iuml
rffit
assay
employ
viral
dose
optim
expect
absolut
valu
decreas
gradual
increas
amount
viral
inocula
fig
b
c
furthermor
valu
sampl
assign
refer
sampl
titer
fell
within
accept
rang
viru
inocula
rang
note
lower
viral
inocula
result
larger
variabl
less
curv
fit
smaller
valu
specif
although
titer
sampl
also
met
accept
criteria
lower
viral
inoculum
trend
increas
variabl
viral
inocula
less
fig
b
support
decreas
valu
therefor
chose
viral
inocula
optim
dose
part
optim
process
also
determin
deaedextran
concentr
rang
rlu
valu
found
increas
increas
amount
deaedextran
rlu
read
plateau
deaedextran
concentr
decreas
sharpli
concentr
deaedextran
reach
decreas
rlu
valu
found
due
cellular
toxic
induc
deaedextran
specif
viabil
cell
decreas
deaedextran
concentr
reach
higher
neutral
assay
although
addit
deaedextran
could
reduc
viru
volum
yield
similar
level
snr
littl
effect
final
result
base
observ
deaedextran
chosen
enhanc
infecti
pseudoviru
without
caus
cytotox
pseudovirusbas
neutral
assay
pbna
assay
intend
use
analys
human
anim
sampl
panel
fifti
human
thirti
mous
serum
sampl
use
evalu
pbna
parallel
rffit
comparison
first
establish
limit
detect
lod
pbna
assay
shown
fig
assay
pbna
human
serum
sampl
found
higher
background
compar
mous
sampl
mean
titer
valu
neg
sampl
standard
deviat
sd
use
calcul
limit
detect
lod
lod
human
serum
sampl
mous
serum
sampl
compar
nation
antirabi
standard
iuml
lod
iuml
iuml
human
mous
serum
sampl
respect
valu
two
intern
control
sampl
initi
assign
use
rffit
test
time
individu
plate
iuml
iuml
b
mean
sd
reproduc
pbna
determin
test
two
intern
control
sampl
three
independ
run
run
two
sampl
test
time
individu
plate
duplic
well
coeffici
variat
cv
rang
intra
assay
inter
assay
fig
total
cv
sampl
b
pbna
respect
rel
lower
rffit
result
test
pbna
within
assign
valu
predetermin
rffit
base
result
gener
pbna
test
valu
rang
assign
sampl
iuml
b
iuml
determin
correl
pbna
rffit
qualit
analys
rabiesspecif
antibodi
serum
sampl
vaccin
human
subject
assay
among
clinic
sampl
identifi
posit
rffit
pbna
assay
respect
fig
qualit
comparison
result
two
assay
show
concord
posit
neg
sampl
kappa
respect
discord
found
seven
sampl
mcnemar
p
analysi
reveal
neutral
antibodi
valu
seven
sampl
determin
pbna
rffit
seven
valu
close
cutoff
valu
iuml
indic
discord
mainli
associ
serum
sampl
low
level
antibodi
ie
near
borderlin
set
posit
valu
correl
two
assay
also
determin
quantit
analys
human
sampl
end
serum
sampl
test
posit
assay
use
determin
correl
found
good
linear
correl
two
assay
p
fig
fit
regress
line
present
equat
pbna
ci
estim
slope
found
p
estim
intercept
p
compar
pbna
valu
rffit
valu
sampl
test
averag
recoveri
pbna
rsd
confirm
correl
two
assay
employ
end
differ
antibodi
concentr
sampl
iuml
iuml
rffit
plot
mean
valu
obtain
two
assay
fig
mean
differ
iuml
sd
differ
iuml
base
plot
limit
agreement
iuml
mean
sd
reveal
differ
posit
sampl
predetermin
assay
fall
within
limit
agreement
collect
data
indic
statist
strong
correl
pbna
rffit
qualit
quantit
analys
clinic
sampl
wherea
former
least
time
sensit
investig
whether
hightit
pseudotyp
viru
prepar
could
use
develop
vivo
assay
rabi
vaccin
evalu
conduct
anim
experi
mice
kunm
mice
km
inocul
pseudoviru
variou
rout
includ
intracrani
subcutan
intramuscular
intraven
inject
turn
intraven
inject
result
detect
bioluminesc
signal
fig
next
investig
murin
strain
best
suitabl
vivo
assay
achiev
km
nih
balbc
intraven
inocul
amount
rabi
pseudotyp
viru
shown
fig
highest
signal
detect
km
mice
hour
postinject
also
determin
optim
weight
km
mice
vivo
assay
km
mice
bodi
weight
rang
gram
inocul
per
mous
shown
fig
lighter
bodi
weight
km
mice
higher
signal
could
detect
follow
intraven
iv
inject
therefor
conclud
intraven
inocul
km
mice
weigh
gram
chosen
conduct
rabi
vaccin
evalu
use
pseudoviru
experi
next
conduct
determin
optim
time
point
signal
detect
mice
follow
iv
inject
end
two
km
mice
inject
pseudoviru
six
hour
postinject
start
monitor
anim
bioluminesc
imag
day
bioluminesc
signal
visual
spleen
liver
one
day
postinocul
day
densiti
signal
increas
reach
highest
level
organ
signal
densiti
began
declin
two
tissu
day
spread
pseudoviru
brain
detect
three
day
postinject
signal
intens
declin
rapidli
complet
disappear
day
observ
larg
expect
given
pseudovir
infect
singleround
event
find
indic
h
postinfect
optim
time
point
vivo
assay
final
compar
vivo
pseudoviru
assay
tradit
mous
assay
employ
wt
rabi
viru
first
determin
dose
pseudoviru
inocul
end
serial
dilut
pseudovirus
inject
intraven
seven
group
mice
micegroup
start
dose
anim
predetermin
pbna
shown
fig
anim
infecti
dose
pseudoviru
found
vivo
protect
assay
pseudoviru
dose
determin
equival
next
investig
correl
vivo
pbna
current
live
virusbas
mous
assay
toward
end
inject
rabiesspecif
immunoglobulin
km
mice
intramuscularli
three
day
challeng
either
wt
viru
pseudoviru
shown
fig
clear
doserespons
observ
pseudoviru
vivo
assay
determin
iu
confid
interv
iu
use
probit
method
fig
tradit
mous
assay
use
live
wt
viru
shown
fig
iu
ci
iu
confirm
serum
sampl
prior
viru
challeng
collect
test
vitro
neutral
activ
use
pbna
found
serum
sampl
pseudoviru
vivo
assay
show
complet
protect
neutral
antibodi
concentr
iuml
higher
two
anim
complet
protect
neutral
titer
found
iuml
live
viru
mous
model
full
protect
could
achiev
neutral
antibodi
level
iuml
greater
collect
data
indic
pseudoviru
vivo
assay
use
assess
effect
antirabi
antibodi
current
vitro
vivo
assay
rabi
vaccin
therapeut
rabiesspecif
immunoglobulin
requir
use
live
wt
rabi
viru
must
handl
level
biocontain
facil
addit
vivo
assay
take
least
two
week
known
labor
intens
clearli
explor
altern
method
facilit
develop
evalu
rabi
vaccin
therapeut
antibodi
pseudovirusbas
neutral
assay
pbna
offer
great
advantag
wt
virusbas
method
versatil
much
safer
handl
versatil
pseudoviru
achiev
pseudotyp
viru
differ
outer
membran
protein
envelop
protein
enabl
infect
varieti
cell
type
pseudoviru
much
safer
viru
essenti
devoid
virul
viral
compon
involv
singl
round
replic
yet
biggest
drawback
pseudoviru
system
harvest
virus
often
low
titer
substanti
limit
applic
particularli
vivo
studi
resolv
issu
systemat
analyz
type
promot
variou
combin
rabiesg
protein
express
plasmid
core
plasmid
express
luciferas
addit
optim
critic
step
highyield
pseudoviru
product
respect
reproduc
vitro
assay
pbna
also
reproduc
tradit
rffit
assay
demonstr
smaller
differ
valu
assign
two
intern
control
sampl
smaller
cv
valu
compar
assign
rffit
serum
titer
calcul
nation
standard
observ
good
agreement
valu
two
assay
howev
pbna
object
less
labor
intens
data
obtain
luminesc
read
oper
rffit
read
result
manual
microscop
biodistribut
pseudoviru
mice
systemat
investig
given
spleen
liver
major
organ
clear
particl
blood
circul
biodistribut
pattern
rabi
pseudoviru
administ
intraven
expectedli
differ
wt
viru
model
viru
given
latter
case
rabi
viru
reach
cn
retrograd
transport
rout
follow
spread
centrifug
along
autonom
sensori
nerv
peripher
pseudoviru
model
bioluminesc
found
brain
hour
time
signal
densiti
began
declin
spleen
liver
suggest
pseudoviru
maintain
neurotrop
properti
nevertheless
spleen
known
biggest
reservoir
monocyt
outnumb
circul
human
mous
monocyt
suscept
rabi
viral
could
also
explain
strong
luminesc
signal
spleen
expect
intracerebr
inject
anim
pseudoviru
bioluminesc
signal
initi
found
mainli
local
brain
follow
redistribut
spleen
liver
biodistribut
pattern
similar
live
wt
viru
given
intracerebr
data
shown
therefor
differ
viral
biodistribut
larg
due
rout
administr
despit
differ
viral
data
gener
pbna
vivo
assay
demonstr
strong
statist
correl
obtain
live
wt
virusbas
assay
short
pbna
vitro
vivo
assay
superior
wt
virusbas
assay
specif
absenc
lethal
wt
viru
whole
experiment
procedur
could
greatli
facilit
develop
rabi
vaccin
therapeut
addit
pseudoviru
vitro
assay
sensit
reproduc
well
less
laborintens
compar
tradit
assay
moreov
pbna
vivo
assay
shorten
experiment
time
week
day
nonetheless
method
prepar
hightit
pseudoviru
optim
vitro
vivo
assay
could
interest
vaccin
develop
regul
alik
atcc
atcc
invitrogen
carlsbad
ca
usa
mdck
atcc
atcc
bsr
institut
pasteur
pari
franc
vero
atcc
cell
maintain
environ
high
glucos
dmem
gibco
supplement
fb
gibco
penicillin
iuml
streptomycin
passag
everi
day
rabv
challeng
standard
kindli
provid
institut
pasteur
pari
franc
passag
bsr
establish
primari
master
work
viru
seed
lot
work
seed
use
rffit
live
viru
anim
model
rabiesneg
human
serum
sampl
kindli
provid
shanghai
raa
blood
product
co
ltd
shanghai
china
specif
determin
rabi
pbna
postvaccin
human
serum
sampl
collect
phase
iii
clinic
trial
rabi
vaccin
produc
vero
cell
chinadrugtrialsgovcn
id
kindli
provid
hualan
biolog
engin
inc
henan
china
healthi
volunt
receiv
rabi
vaccin
intramuscularli
day
dose
dose
dose
serum
sampl
collect
day
second
vaccin
collect
day
nation
standard
antirabi
immunoglobulin
collect
postvaccin
individu
establish
calibr
intern
standard
antirabi
immunoglobulin
human
nibsc
code
rai
two
serum
sampl
use
intern
control
rffit
also
collect
postvaccin
individu
calibr
use
intern
standard
assign
valu
nation
standard
iuml
assign
valu
intern
control
sampl
b
iuml
iuml
averag
sd
respect
written
inform
consent
obtain
volunt
firefli
luciferas
fluc
gene
clone
gift
john
schiller
addgen
plasmid
subsequ
insert
bamh
ixho
site
invitrogen
carlsbad
ca
gener
plasmid
promot
fulllength
cmv
kindli
provid
yime
shao
china
cdc
cag
kind
gift
yuelei
shen
biocytogen
co
ltd
china
ltr
kindli
provid
xiaoyun
wu
univers
alabama
use
replac
cmv
promot
mlu
inh
digest
infus
ligat
clontech
gener
pscmvfluc
pcagfluc
pltrfluc
respect
fluc
gene
flucexpress
plasmid
replac
g
protein
gene
bamh
ixho
digest
gener
pscmvcvsg
pcagcvsg
pltrcvsg
respect
fluc
scmvfluc
pscmvfluc
amplifi
clone
respect
gener
use
restrict
endonucleas
digest
hpa
direct
ligat
infus
similarli
scmvfluc
construct
gener
primer
use
section
list
tabl
product
rabi
pseudovirus
mammalian
cell
accomplish
use
method
similar
hiv
pseudoviru
describ
briefli
mammalian
cell
cotransfect
rabi
g
protein
express
plasmid
hiv
backbon
vector
use
lipofectamin
invitrogen
carlsbad
ca
accord
manufactur
instruct
fortyeight
hour
post
transfect
pseudoviruscontain
cultur
supernat
harvest
filter
pore
size
store
lower
aliquot
use
tissu
cultur
infecti
dose
rabi
pseudoviru
batch
determin
use
singleus
aliquot
pseudoviru
bank
stock
use
avoid
inconsist
could
result
repeat
freezingthaw
cycl
serial
fold
dilut
dilut
total
made
hexapl
well
cultur
plate
initi
dilut
last
column
design
neg
control
without
pseudoviru
trypsintr
mammalian
cell
adjust
concentr
mix
deaedextran
seed
well
h
incub
environ
cultur
medium
aspir
gentli
leav
well
brightglo
luciferas
reagent
promega
madison
wi
ad
well
follow
min
incub
room
temperatur
lysat
transfer
solid
black
plate
luminesc
detect
use
glomax
micropl
luminomet
promega
fitchburg
wi
calcul
use
reedmuench
neutral
measur
reduct
luc
gene
express
describ
previous
hiv
pseudoviru
neutral
inhibitori
concentr
defin
serum
dilut
rel
light
unit
rlu
reduc
compar
viru
control
well
viru
cell
subtract
background
rlu
control
group
cell
brief
pseudoviru
incub
serial
dilut
test
sampl
dilut
stepwis
manner
duplic
hour
togeth
viru
control
cell
control
well
hexapl
freshli
trypsin
cell
ad
well
follow
hour
incub
environ
luminesc
measur
describ
section
pseudoviru
titrat
valu
calcul
nonlinear
regress
ie
log
inhibitor
vs
respons
four
paramet
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
neutral
antibodi
titer
calcul
compar
nation
antirabi
standard
iuml
sampl
neutral
antibodi
titer
equal
iuml
defin
adequ
protect
therefor
determin
posit
neutral
antibodi
titer
genuin
rabi
viru
determin
rffit
describ
briefli
incub
serial
dilut
test
sampl
dilut
stepwis
manner
duplic
hour
next
bsr
cell
ad
well
incub
environ
h
final
cell
fix
chill
aceton
min
stain
fitcconjug
antirabi
n
monoclon
antibodi
fujirebio
diagnost
inc
malvern
pa
min
record
fluoresc
rate
per
well
visual
fluoresc
microscop
averag
infect
rate
duplic
sampl
determin
neutral
antibodi
titer
determin
compar
nation
standard
use
calcul
method
report
test
intern
control
sampl
b
includ
ensur
effect
assay
valu
b
lie
predetermin
rang
respect
mice
hous
maintain
accord
relev
nation
guidelin
regul
procedur
carri
accord
protocol
approv
institut
anim
care
use
committe
nation
institut
food
drug
control
nifdc
anim
obtain
institut
laboratori
anim
resourc
nifdc
mice
inocul
human
rabi
immunoglubin
hrig
intramuscularli
three
day
viru
challeng
bled
viru
challeng
neutral
titer
mous
serum
sampl
determin
use
rabi
pbna
pseudovirusin
vivo
challeng
assay
mice
inocul
differ
volum
pseudovirus
ie
ml
intramuscularli
ml
intracerebr
ml
subcutan
intraven
wt
viru
challeng
assay
mice
inocul
volum
ml
intramuscularli
pseudoviru
challeng
assay
bioluminesc
detect
mous
wt
viru
challeng
surviv
rate
sign
rabi
record
group
time
period
day
challeng
bioluminesc
analys
conduct
use
ivislumina
iii
imag
system
xenogen
baltimor
md
describ
briefli
mice
anesthet
intraperiton
ip
inject
pentobarbit
sodium
mgkg
bodi
weight
follow
ip
inject
substrat
dluciferin
bodi
weight
xenogencalip
corp
alameda
ca
seven
minut
later
bioluminesc
detect
mous
imag
chamber
acquisit
time
min
rel
bioluminesc
calcul
use
photonpersecond
mode
normal
imag
area
total
flux
previous
one
way
analysi
varianc
use
assess
differ
pseudoviru
titer
gener
variou
cell
line
differ
cell
number
pair
comparison
also
conduct
use
student
test
pair
test
mcnemar
kappa
valu
use
assess
differ
qualit
result
obtain
pbna
rffit
pearson
correl
coeffici
employ
analyz
strength
linear
valu
pbna
rffit
compar
quantit
result
obtain
posit
sampl
detect
assay
fit
regress
model
compar
test
two
tail
hypothesi
slope
intercept
blandaltman
method
ie
scatter
plot
differ
pair
measur
mean
valu
sampl
use
assess
magnitud
disagr
two
graph
gener
use
prism
softwar
graphpad
san
diego
ca
cite
articl
nie
j
et
al
develop
vitro
vivo
rabi
viru
neutral
assay
base
hightit
pseudoviru
system
sci
rep
doi
publish
note
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
